FTXH - First Trust Nasdaq Pharmaceuticals ETF
| Assets | $20.65M |
| NAV | $25.82 |
| Expense Ratio | 0.60% |
| PE Ratio | 22.71 |
| Beta (5Y) | 0.92 |
| Dividend (ttm) | $0.23 |
| Dividend Yield | 0.89% |
| Ex-Dividend Date | Mar 25, 2021 |
| 1-Year Return | - |
| Trading Day | April 16 |
| Last Price | $25.96 |
| Previous Close | $25.83 |
| Change ($) | 0.14 |
| Change (%) | 0.52% |
| Day's Open | 25.68 |
| Day's Range | 25.68 - 25.96 |
| Day's Volume | 2,094 |
| 52-Week Range | 21.16 - 27.08 |
Fund Description
The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of the Nasdaq US Smart Pharmaceuticals Index. The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depository receipts that comprise the index. The index is designed to provide exposure to U.S. companies comprising the pharmaceutical sector that have been selected based upon their liquidity and weighted based upon their cumulative score on three investing factors: volatility, value and growth. It is non-diversified.
| Asset Class Equity | Sector Large Cap |
| Region North America | Inception Date Sep 20, 2016 |
| Exchange NASDAQ | Ticker Symbol FTXH |
| Index Tracked Nasdaq US Smart Pharmaceuticals Index | |
Top 10 Holdings
61.47% of assets| Name | Symbol | Weight |
|---|---|---|
| United Therapeutics | UTHR | 9.57% |
| Bristol-Myers Squibb | BMY | 8.34% |
| Johnson & Johnson | JNJ | 8.03% |
| Horizon Therapeutics | HZNP | 7.35% |
| AbbVie | ABBV | 7.17% |
| Pfizer | PFE | 4.45% |
| Prestige Consumer Healthcare | PBH | 4.28% |
| Merck | MRK | 4.19% |
| Abbott Laboratories | ABT | 4.10% |
| Jazz Pharmaceuticals | JAZZ | 3.97% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Mar 25, 2021 | $0.0771 | Mar 31, 2021 |
| Dec 24, 2020 | $0.0644 | Dec 31, 2020 |
| Sep 24, 2020 | $0.043 | Sep 30, 2020 |
| Jun 25, 2020 | $0.046 | Jun 30, 2020 |
| Mar 26, 2020 | $0.0591 | Mar 31, 2020 |
| Dec 13, 2019 | $0.0411 | Dec 31, 2019 |
Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging progress in coronavirus vaccine development as the outbreak worsens.
Healthcare Q4 results seem robust given that it is the fourth-best sector from a revenue growth look and the sixth-strongest in terms of earnings growth.
Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging progress in coronavirus vaccine development.
The slew of Q3 results have led to mixed trading in pharma ETFs over the past month.
The First Trust Nasdaq Pharmaceuticals ETF (FTXH) has hit a new 52-week high. Are more gains in store?
Total earnings of 66.4% of the healthcare market capitalization that has reported so far are up 4.4% on revenue growth of 4%.
ETF Spotlight: Pharmaceuticals driven higher by Pfizer
CNBC'S Morgan Brennan takes a look at pharmaceutical as Pfizer's positive vaccine news has led the sector higher.
Strong results led to solid trading in pharma ETFs over the past week.
Robust results led to solid trading in pharma ETFs in a month.
Despite robust results, pharma ETFs have been trending downward in a month.
Despite such robust results, pharma ETFs have been trending downward in a month.